Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free GNCAQ Stock Alerts

Genocea Biosciences (GNCAQ) Competitors

Genocea Biosciences logo
Compare

GNCAQ vs. SCPS, VRPX, VAXX, ARDS, and TRVN

Should you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include Scopus BioPharma (SCPS), Virpax Pharmaceuticals (VRPX), Vaxxinity (VAXX), Aridis Pharmaceuticals (ARDS), and Trevena (TRVN). These companies are all part of the "pharmaceutical products" industry.

How does Genocea Biosciences compare to Scopus BioPharma?

Genocea Biosciences (NASDAQ:GNCAQ) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A N/A N/A
Scopus BioPharma N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/AN/AN/AN/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Genocea Biosciences has a beta of 2.53, indicating that its share price is 153% more volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Scopus BioPharma Neutral

Summary

Genocea Biosciences beats Scopus BioPharma on 1 of the 1 factors compared between the two stocks.

How does Genocea Biosciences compare to Virpax Pharmaceuticals?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Genocea Biosciences' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
Genocea Biosciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
Genocea BiosciencesN/AN/AN/AN/AN/A

Virpax Pharmaceuticals has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 2.53, meaning that its share price is 153% more volatile than the S&P 500.

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Genocea Biosciences Neutral

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Virpax Pharmaceuticals and Genocea Biosciences tied by winning 3 of the 6 factors compared between the two stocks.

How does Genocea Biosciences compare to Vaxxinity?

Vaxxinity (NASDAQ:VAXX) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Vaxxinity has a beta of -74.37, meaning that its share price is 7,537% less volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 2.53, meaning that its share price is 153% more volatile than the S&P 500.

Company Net Margins Return on Equity Return on Assets
VaxxinityN/A N/A N/A
Genocea Biosciences N/A N/A N/A

82.9% of Vaxxinity shares are held by institutional investors. 64.1% of Vaxxinity shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxxinityN/AN/A-$56.93M-$0.45N/A
Genocea BiosciencesN/AN/AN/AN/AN/A

In the previous week, Vaxxinity's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Vaxxinity Neutral
Genocea Biosciences Neutral

Summary

Vaxxinity beats Genocea Biosciences on 3 of the 4 factors compared between the two stocks.

How does Genocea Biosciences compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Genocea Biosciences Neutral

Aridis Pharmaceuticals has a beta of 49.48, suggesting that its share price is 4,848% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 2.53, suggesting that its share price is 153% more volatile than the S&P 500.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Genocea Biosciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.03
Genocea BiosciencesN/AN/AN/AN/AN/A

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Aridis Pharmaceuticals beats Genocea Biosciences on 4 of the 4 factors compared between the two stocks.

How does Genocea Biosciences compare to Trevena?

Genocea Biosciences (NASDAQ:GNCAQ) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Trevena Neutral

Genocea Biosciences has a beta of 2.53, meaning that its share price is 153% more volatile than the S&P 500. Comparatively, Trevena has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A N/A N/A
Trevena N/A N/A -119.55%

Genocea Biosciences has higher earnings, but lower revenue than Trevena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/AN/AN/AN/A
Trevena$443K0.02-$40.29M-$47.04N/A

13.6% of Trevena shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 2.7% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Trevena beats Genocea Biosciences on 4 of the 6 factors compared between the two stocks.

Get Genocea Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNCAQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNCAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

GNCAQ vs. The Competition

Export
MetricGenocea BiosciencesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$5K$328.16M$6.25B$11.87B
Dividend YieldN/AN/A2.73%5.21%
P/E Ratio0.00N/A29.0428.47
Price / SalesN/A189.48476.6160.92
Price / CashN/A22.4427.6236.52
Price / BookN/A4.739.676.67
Net IncomeN/A-$132.96M$3.55B$332.53M

Genocea Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNCAQ
Genocea Biosciences
N/AN/AN/AN/A$5KN/AN/A70
SCPS
Scopus BioPharma
N/A$0.00
flat		N/AN/A$17KN/AN/A9
VRPX
Virpax Pharmaceuticals
N/A$0.01
flat		N/AN/A$14KN/AN/A7
VAXX
Vaxxinity
N/A$0.00
-99.5%		N/AN/A$13KN/AN/A90
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/AN/A$11KN/A0.0030

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GNCAQ) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel